Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Vinca Minor
Generic Name
Vinca Minor
Active Ingredient
Vinca MinorCategory
Non-Standardized Plant Allergenic Extract [EPC]
Variants
8
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 6 [hp_C]/1 | PELLET | ORAL | 37662-1317 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-1318 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-1320 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Vinca Minor, you must consult a qualified healthcare professional.
| 200 [hp_C]/1 | PELLET | ORAL | 37662-1321 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-1323 |
| 1 [hp_Q]/1 | PELLET | ORAL | 37662-1324 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-1322 |
| 30 [hp_C]/1 | PELLET | ORAL | 37662-1319 |
Detailed information about Vinca Minor
Vinca Minor, also known as Lesser Periwinkle, is primarily utilized in clinical immunology as a Non-Standardized Plant Allergenic Extract [EPC] for the diagnosis and treatment of specific botanical allergies.
Dosage for Vinca Minor allergenic extracts is highly individualized and must be determined by a physician based on the patient's sensitivity levels.
For Skin Prick Testing (SPT), a single drop of the 1:20 w/v or 1:10 w/v extract is applied to the forearm or back, followed by a superficial puncture of the skin. Results are read after 15 to 20 minutes.
Immunotherapy typically follows a two-phase schedule:
Vinca Minor extracts may be used in children, but extreme caution is required. Dosing follows the same weight/volume titration principles as adults, but the starting dose may be even more conservative depending on the child's history of asthma or previous systemic reactions. There is no specific age cutoff, but immunotherapy is rarely started in children under the age of 5 due to the difficulty of communicating symptoms of a systemic reaction.
No specific dosage adjustments are provided in the manufacturer labeling for renal impairment, as the systemic protein load is negligible. However, patients with severe renal disease may be at higher risk if epinephrine (the treatment for overdose/anaphylaxis) needs to be administered.
No dosage adjustments are required for hepatic impairment. The metabolism of allergenic proteins is not dependent on hepatic CYP450 pathways.
Geriatric patients (over 65) should be evaluated for cardiovascular stability before starting Vinca Minor immunotherapy. If the patient is taking beta-blockers for hypertension or heart disease, immunotherapy may be contraindicated because these drugs interfere with the action of epinephrine.
This medication is NOT for self-administration. It must be administered by a healthcare professional in a clinical setting.
If a dose in the build-up phase is missed, the next dose may need to be reduced or the previous dose repeated to ensure safety.
An "overdose" in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance, leading to a systemic reaction.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to alter the schedule or administer these extracts at home.
Most patients undergoing treatment with Vinca Minor allergenic extracts will experience local reactions. These are generally not dangerous but can be uncomfortable.
Vinca Minor allergenic extract is a potent biological product. Its safety depends entirely on correct administration and patient selection. It is not a "cure" for allergies in the traditional sense but a long-term management strategy that carries inherent risks of systemic allergic reactions.
No specific FDA black box warning exists for Vinca Minor individually, but it falls under the class-wide warning for all Non-Standardized Allergenic Extracts. This warning emphasizes that:
Vinca Minor allergenic extract is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not the extract itself, which is a protein, but the risk of a systemic reaction (anaphylaxis). Anaphylaxis in a pregnant mother can cause a sudden drop in blood pressure and oxygen, leading to fetal distress or miscarriage. Most allergists will not start a new Vinca Minor build-up schedule during pregnancy but may continue a maintenance dose if the patient is tolerating it well.
It is not known whether the components of Vinca Minor extract are excreted in human milk. However, because these are proteins that are digested in the infant's gut, the risk to a nursing infant is considered extremely low. The benefits of the mother's allergy control usually outweigh the theoretical risks.
As noted, Vinca Minor is safe for use in children, provided they are old enough to cooperate with the injection process and describe any symptoms of a reaction. Studies have shown that early immunotherapy in children can sometimes prevent the development of new allergies (the "allergic march") and reduce the risk of developing asthma.
Vinca Minor allergenic extract acts as an immunomodulator. In diagnostic use, it triggers a localized Type I Hypersensitivity reaction via IgE-mediated mast cell degranulation. In therapeutic use (AIT), it induces Peripheral T-cell Tolerance. This involves the generation of regulatory T-cells (Tregs) that produce IL-10 and TGF-beta, which suppress the allergic Th2 response and promote the production of non-inflammatory IgG4 antibodies.
The onset of action for diagnostic testing is rapid (15-20 minutes). For immunotherapy, the onset is slow; patients typically do not see a reduction in allergy symptoms until they have reached the maintenance phase, which can take 6 to 12 months. The duration of effect can be long-lasting, often persisting for years after the 3-5 year treatment course is completed.
| Parameter | Value |
|---|---|
Common questions about Vinca Minor
Vinca Minor allergenic extract is primarily used for the diagnosis and treatment of specific allergies to the Lesser Periwinkle plant. In a diagnostic setting, it is used in skin prick tests to confirm if a patient's respiratory or skin symptoms are caused by an allergy to this plant. For treatment, it is used in allergen immunotherapy (allergy shots) to gradually desensitize the patient's immune system. This long-term process involves regular injections of increasing amounts of the extract. The goal is to reduce the severity of allergic rhinitis or asthma symptoms over several years. It is not used for general health or as a vitamin supplement in this clinical form.
The most common side effects are localized to the site of the injection or skin test. Patients frequently experience redness, itching, and a small raised bump (wheal) at the site where the extract was administered. These reactions usually appear within minutes and resolve within a few hours. Some patients may also experience 'delayed' local reactions, where swelling occurs several hours later. While these are common and usually harmless, they should be reported to your doctor. Systemic side effects like sneezing or fatigue are less common but can occur.
It is strongly recommended to avoid alcohol on the days you receive a Vinca Minor injection. Alcohol can cause your blood vessels to dilate, which may lead to faster absorption of the allergen into your bloodstream. This increased absorption rate can raise the risk of a systemic allergic reaction or make a reaction more severe if it occurs. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as feeling flushed or lightheaded. To ensure maximum safety, wait at least 24 hours after your injection before consuming alcohol. Always consult your allergist for their specific clinical policy regarding alcohol.
Vinca Minor immunotherapy is generally not started during pregnancy because of the risk of anaphylaxis, which can be dangerous for both the mother and the fetus. However, if a woman is already on a stable maintenance dose and is tolerating the injections well, her doctor may choose to continue the treatment. The extract itself is made of proteins and is not known to cause birth defects. The primary concern is the potential for a sudden drop in maternal blood pressure during a reaction. If you become pregnant while receiving Vinca Minor shots, notify your allergist immediately to discuss a safe plan. Most doctors prioritize maternal safety and will adjust the dose accordingly.
Vinca Minor immunotherapy is a slow-acting treatment that requires patience. Most patients do not notice a significant improvement in their allergy symptoms during the initial 'build-up' phase, which lasts 3 to 6 months. Improvements typically begin to appear once the maintenance dose is reached. It often takes 6 to 12 months of consistent treatment to see a clinical reduction in hay fever or asthma symptoms. For the best long-term results, the treatment is usually continued for 3 to 5 years. This duration helps the immune system 'remember' the tolerance even after the injections stop.
Yes, you can stop taking Vinca Minor injections suddenly without experiencing physical withdrawal symptoms like those seen with some medications. However, stopping the treatment before the recommended 3-to-5-year course is finished usually means your allergies will eventually return to their original severity. If you stop during the build-up phase, you will likely receive no long-term benefit at all. If you need to stop due to side effects or lifestyle changes, discuss it with your allergist first. They may be able to adjust your schedule or dose to make the treatment more manageable for you.
If you miss a dose of Vinca Minor, you should contact your allergist's office to reschedule as soon as possible. Do not attempt to 'double up' on your next dose. Because immunotherapy relies on a careful build-up of tolerance, missing a dose for more than a week or two may require your doctor to reduce your next dose for safety. If a significant amount of time has passed (usually more than 4 weeks), you may need to restart the build-up process from a lower concentration. Consistent attendance is key to both the safety and the effectiveness of the treatment.
There is no clinical evidence to suggest that Vinca Minor allergenic extracts cause weight gain. The extract consists of a very small amount of protein and glycerin, which has no significant caloric value or metabolic effect on body weight. If you experience weight changes while on immunotherapy, it is likely due to other factors, such as lifestyle changes or other medications you may be taking (like oral steroids for asthma). Always discuss unexpected weight changes with your primary care physician to rule out other underlying causes. Immunotherapy itself is considered weight-neutral.
Vinca Minor can be taken with many medications, but there are some critical exceptions. You must tell your doctor if you are taking beta-blockers, which are often prescribed for high blood pressure, heart conditions, or migraines. Beta-blockers can make allergic reactions more dangerous and prevent life-saving epinephrine from working. Other medications like ACE inhibitors or MAOIs may also require special consideration. Most standard medications, including vitamins and common pain relievers, do not interact with the extract. Always provide your allergist with a complete and updated list of all your medications and supplements.
Vinca Minor allergenic extract is a biological product rather than a standard chemical drug, so the term 'generic' does not apply in the traditional sense. However, multiple biological manufacturers may produce their own versions of Vinca Minor extract. These are generally considered interchangeable by allergists, but switching between different manufacturers' products may require a temporary dose reduction to ensure safety, as non-standardized extracts can vary slightly in potency. Your allergist will typically source the extract from a reputable biological laboratory that follows FDA Good Manufacturing Practices.
> Warning: Stop taking Vinca Minor immunotherapy and call your doctor or emergency services immediately if you experience any of the following symptoms of anaphylaxis:
There are no known long-term "toxic" side effects of Vinca Minor allergenic extracts when used correctly. The primary long-term outcome is the intended "side effect" of immune tolerance. However, some patients may develop persistent subcutaneous nodules (small, hard lumps under the skin) at the site of repeated injections. These are generally benign but should be monitored by a physician.
While Vinca Minor extracts may not have a specific "Black Box" in the same way a pharmaceutical drug like warfarin does, all FDA-approved allergenic extracts carry a General Warning for Anaphylaxis. The labeling strictly states that these products must only be used by physicians experienced in the treatment of life-threatening systemic reactions and that patients must be observed for a minimum of 30 minutes post-injection.
Report any unusual symptoms, especially those occurring within the first hour of treatment, to your healthcare provider immediately.
Generally, Vinca Minor does not cause sedation. However, if a patient experiences a systemic reaction or receives antihistamines/epinephrine for a reaction, they should not drive or operate machinery until they are fully recovered and cleared by a medical professional.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can speed up the absorption of the allergen and potentially increase the risk or severity of a systemic reaction.
If a patient experiences a severe systemic reaction, the physician must perform a risk-benefit analysis to decide whether to continue. Discontinuing Vinca Minor immunotherapy does not cause "withdrawal" symptoms, but the patient's original allergy symptoms will likely return over time.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Vinca Minor.
There are no known direct interactions between Vinca Minor extract and specific foods. However, patients with "Oral Allergy Syndrome" may find that certain fruits or vegetables cross-react with Vinca Minor proteins, potentially increasing their overall "allergic load" on the day of an injection.
For each major interaction, the mechanism involves either a pharmacodynamic interference (blocking the rescue medication) or an immunological additive effect (increasing the risk of a reaction). Management always involves a thorough medication review by the allergist before the first dose.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially blood pressure or heart medications.
Patients allergic to Vinca Minor may show cross-sensitivity to other members of the Apocynaceae family. While less common than grass or ragweed cross-reactivity, clinicians should be aware of potential reactions to related ornamental plants. There is no cross-reactivity between Vinca Minor allergenic extract and the vinca alkaloid chemotherapy drugs.
> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung health, before prescribing Vinca Minor.
In patients over 65, the decision to use Vinca Minor must be balanced against the patient's cardiovascular health. Elderly patients are more likely to have undiagnosed coronary artery disease or be taking medications (like beta-blockers) that make immunotherapy more dangerous. Renal and hepatic changes associated with age do not significantly affect the use of this extract.
No dosage adjustments are required. However, clinicians should ensure the patient can tolerate the fluid shifts and medications (like IV fluids or pressors) that might be required in the event of an emergency.
No dosage adjustments are required. The extract does not undergo hepatic metabolism.
> Important: Special populations require individualized medical assessment by an allergy specialist.
| Protein Binding | N/A |
| Half-life | Variable (Proteins degraded within hours/days) |
| Tmax | 15-30 minutes (for local reaction) |
| Metabolism | Endogenous proteases |
| Excretion | Renal (as amino acids/peptides) |
Vinca Minor extract is a complex biological mixture. It contains various proteins, including glycoproteins and polysaccharides derived from the plant's leaves and pollen. It is typically prepared in a 50% glycerin solution with 0.45% phenol as a preservative. The molecular weight of the active allergenic proteins typically ranges from 10 to 70 kDa.
Vinca Minor belongs to the class of Non-Standardized Plant Allergenic Extracts. Related medications include extracts for Ragweed, Timothy Grass, and Oak, although each is specific to the patient's individual allergy profile.